H.C. Wainwright analyst Matthew Keller initiated coverage of GRI Bio (GRI) with a Buy rating and $10 price target GRI is a clinical stage company developing therapies that modulate natural killer T cell behavior and activity in inflammatory diseases, the analyst tells investors in a research note. The firm believes the combination of two immunomodulatory assets and a library of potentially applicable compounds positions GRI Bio to progress its pipeline in-house, while taking advantage of potential strategic partnerships.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRI:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue